Resumen
To the Editor: Winterbauer et al. (N Engl J Med 294:919–921, 1976) present convincing evidence that chrysotherapy may induce diffuse pulmonary injury. We wish to re-emphasize two commonly accepted precautions in the use of chrysotherapy, pertinent to the cases reported. Phenylbutazone and gold sodium thiomalate were given concomitantly in Case 1. A number of authorities123state that pyrazolon-derived drugs (phenylbutazone, oxyphenbutazone) are interdicted during chrysotherapy. Both drugs produce bone-marrow suppression and aplasia, and one drug may enhance the toxic potential of the other.3Furthermore, the causative agent cannot be identified if mucocutaneous lesions develop during combined drug treatment, and.
| Idioma original | Inglés |
|---|---|
| Páginas (desde-hasta) | 506-507 |
| Número de páginas | 2 |
| Publicación | New England Journal of Medicine |
| Volumen | 295 |
| N.º | 9 |
| DOI | |
| Estado | Publicada - 26 ago. 1976 |
Huella
Profundice en los temas de investigación de 'Pulmonary Reaction to Chrysotherapy'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver